Main Article Content
Background. The World Health Organization (WHO) has identified diabetes mellitus (DM) as a non-communicable epidemic of the XXI century. Cardiovascular pathology is a major cause of death for these patients. The purpose was to study the indicators of heart rate variability (HRV) in patients with type 2 DM, depending on the course of the disease, and HRV changes after the management of hyperglycemia. Materials and methods. We examined 53 type 2 DM patients and 10 healthy controls. Laboratory tests include determination of C-peptide, glycated hemoglobin (HbA1c), serum creatinine and urinary albumin concentration (UAC). All subjects underwent continuous glucose monitoring and 24-hour Holter monitoring at the same time. The patients were divided into 2 groups according to the НbА1с level: group 1 (n = 23) with НbА1с ≤ 7.0 % and group 2 (n = 30) with НbА1с > 7.0 %. The groups were divided into subgroups according to the absence (a) or presence (b) of hypoglycemia. The patients were re-examined after 6 months of glucose-lowering therapy modification. Results. HRV parameters did not differ significantly between the groups and subgroups of type 2 DM patients (p > 0.05). Both groups and subgroups, as well as the whole basic group of type 2 DM patient, had a significant decrease in SDNN daily, pNN50% daily, VLF daily, HF daily indicators compared with control subjects (р < 0.05). There were no statistically significant differences in daily TP between the control group and subgroup 1а only (р > 0.05). LF daily level was significantly lower compared to control only to all patients with type 2 DM. Daily LF/HF ratio was significantly higher in all subgroups of both groups than the control one (р < 0.05). Conclusions. Type 2 DM patients had significantly lower HRV, which mainly consists of SDNN, TP, VLF, HF LF/HF ratio. Six months after glucose-lowering therapy modification, we received a significant increase in most HRV indicators, except for LF. Main changes were observed in pNN50% daily (+50 %), pNN50% day (+50 %), RMSSD day (+43.5 %), RMSSD daily (+28.6 %), HF (+133.1 % – daily, +172.2 % — day, +57.5 % — at night) and a decrease in LF/HF ratio (–42.9 % — daily, –46.2 % — day, –32.7 % — at night) (p < 0.05). The results clearly demonstrate the restoration of the cardiac vagosympathetic balance due to compensation of carbohydrate metabolism.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
International Diabetes Federation. IDF Diabetes Atlas. 9th ed. 2019. Available from: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf.
International Diabetes Federation. Diabetes and cardiovascular disease. Brussels, Belgium: International Diabetes Federation, 2016. Available from: https://idf.org/our-activities/care-prevention/cardiovascular-disease/cvd-report.html#sub-content-tab-nav.
Madonna R, Pieragostino D, Balistreri CR, et al. Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. Vascul Pharmacol. 2018;S1537-1891(17)30322-1. doi:10.1016/j.vph.2018.01.009.
Vaidya V, Gangan N, Sheehan J. Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):487–497. doi:10.1586/14737167.2015.1024661.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. Published 2018 Jun 8. doi:10.1186/s12933-018-0728-6.
Khudyakova LA, Bagatenkova AI, Kulakhmetov DR. Spectral method of analysis of heart rhythm variability. Bulletin of Kyiv polytechnic institute. Series instrument making. 2018;1:138–44. doi:10.20535/1970.55(1).2018.135838. (in Ukrainian).
Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996;17(3):354–381.
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986. doi:10.1056/NEJM199309303291401.
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi:10.1056/NEJMoa0802987.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019;367:l5887. doi:10.1136/bmj.l5887.
Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care. 2018;41(11):2275–2280. doi:10.2337/dc18-1581.
Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391(10128):1367–1377. doi:10.1016/S0140-6736(18)30297-6.
Spallone V. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J. 2019;43(1):3–30. doi:10.4093/dmj.2018.0259.
Nganou-Gnindjio CN, Mba CM, Azabji-Kenfack M, et al. Poor glycemic control impacts heart rate variability in patients with type 2 diabetes mellitus: a cross sectional study. BMC Res Notes. 2018;11(1):599. doi:10.1186/s13104-018-3692-z.
Koçer A, Aktürk Z, Maden E, Taşçı A. Orthostatic Hypotension and Heart Rate Variability as Signs of Cardiac Autonomic Neuropathy in Diabetes Mellitus. Eur J Gen Med. 2005;2(1):5-9. doi:10.29333/ejgm/82257.
Trivedi GY, Saboo B, Singh RB, Maheshwari A, Sharma K, Verma N. Can decreased heart rate variability be a marker of autonomic dysfunction, metabolic syndrome and diabetes? J Diabetol. 2019;10(2):48-56. doi:10.4103/jod.jod_17_18.